Avantor/$AVTR
1D1W1MYTD1Y5YMAX
Capital at risk
About Avantor
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
- Ticker
- $AVTR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 13,500
- Headquarters
- Radnor, United States
- Website
- www.avantorsciences.com
Avantor Metrics
BasicAdvanced
$10B
-
-$0.85
0.89
-
Price and volume
Market cap
$10B
Beta
0.89
52-week high
$16.05
52-week low
$7.27
Average daily volume
7.7M
Financial strength
Current ratio
1.782
Quick ratio
1.046
Long term debt to equity
0.65
Total debt to equity
0.657
Interest coverage (TTM)
2.39%
Profitability
EBITDA (TTM)
944
Gross margin (TTM)
31.83%
Net profit margin (TTM)
-8.81%
Operating margin (TTM)
8.01%
Effective tax rate (TTM)
-22.46%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
2.69%
Return on equity (TTM)
-9.70%
Valuation
Price to revenue (TTM)
1.589
Price to book
1.85
Price to tangible book (TTM)
-4.49
Price to free cash flow (TTM)
22.93
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
0.671
Growth
Revenue change (TTM)
-1.57%
Earnings per share change (TTM)
-184.64%
3-year revenue growth (CAGR)
-2.94%
3-year earnings per share growth (CAGR)
10.97%
What the Analysts think about Avantor
Analyst ratings (Buy, Hold, Sell) for Avantor stock.
Analyst projections of the future price of Avantor stock.
Bulls say / Bears say
BMP’s current sales decline may be a lagging indicator: order intake grew at double-digit rates and book-to-bill was 1.1x. Avantor also expanded its RIM single-use bioprocessing range across Asia-Pacific, improving its access to a key biopharma manufacturing market. (Yahoo Finance, Yahoo Finance)
Cash generation gives the turnaround room to work: Avantor produced $142.8 million of free cash flow in Q2 and used $112.1 million to repay debt. It maintained its $500 million-$550 million full-year free-cash-flow target while raising 2026 adjusted EPS guidance to $0.80-$0.83. (Avantor, The Motley Fool)
Bioscience & Medtech Products remains the weak link: organic sales fell 5.6% in Q2 and adjusted operating income dropped to $117.6 million from $131.4 million. That keeps pressure on a higher-margin part of the portfolio. (Avantor)
The Q2 earnings quality was poor despite stable reported sales. Net income fell to $38.1 million from $64.7 million, while adjusted net income declined to $143.3 million from $161.2 million and organic revenue fell 0.4%. (Avantor)
Avantor still carries substantial financial risk, with net debt of about $3.4 billion and adjusted net leverage of 3.3x at the end of Q2. Freight inflation and a stronger dollar are additional pressures on the company’s unchanged full-year EBITDA margin target. (The Motley Fool, Exa)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
Avantor Financial Performance
Revenues and expenses
Avantor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Avantor News
AllArticlesVideos
Funds containing Avantor
AllUSDGBPEUR
Fund name | Fund size | $AVTR weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.29% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.29% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.20% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.20% |
iShares MSCI World Small Cap$WSML | $9B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.